The list keeps growing - check out No 6!30 Apr 2021 11:25
1/ Genedrive 96-SARS-COV-2kit
- Huge worldwide potential
- 97.6% sensitivity and 98.2% specificity, compared to poor lateral flow test performance (sometimes as high as 50% false positives)
- Agreement with BC started 28th Jan 2021. Sales will materialise, though lead times and sales cycles should be considered
- Regulatory approval for Thailand
- FDA frustrating, though the pace of approvals is accelerating
2/ Pathogen Detection (Bioplex): supplier to US military
- Development contract worth owner 10 million
- 500 kits over 3 years
- Partnership with MountainHorse: this will help develop a broader customer base
3/ Antibiotic induced hearing loss test
- World first
- Worldwide neo-natal hearing loss market worth 35-50 million annually (very niche market)
- Launch summer 2021 to UK and Ireland. Worldwide potential thereafter
- 100% accuracy in testing
4/ World first decentralised qualitative molecular HCV test
- Routes to market impacted by COVID
- Good medium to long-term potential
- High efficacy in a recent peer reviewed study
5/ Listed on the PHE chosen contractors list
- Potential for a share of the 3 billion budgeted future spend
6/ Regulatory approval for Indian market
- High test efficacy; 100% specificity and 100% sensitivity
- Access to a market equivalent to 17.7% of the total world population
- Divoc already in place
In Development
1/ Genedrive Saliva Test
- 15/20 minute rapid turnover
- Target market: schools/offices/travel etc.
- High accuracy unlike lateral flow tests
2/ Point of care test for tuberculosis
- On hold due to COVID, though good future potential for 2022/2023.
Other important points
- Healthy cash to burn ratio
- High stock levels to fulfil orders
- European ministry of health opportunity. Potential for a low double digit millions of pound order to be delivered in a short period of time
These are the facts but do your own research and make up your own minds.
Good luck all
Sign In
Follow the stocks
